CN Patent

CN121358726A — 取代的杂环化合物

Assigned to Capital Pharmaceutical Holdings Beijing Co ltd · Expires 2026-01-16 · 0y expired

What this patent protects

本申请涉及式(I)所示的一类具有生物抑制活性的取代的杂环化合物及其制备方法和用途。所述用途包括式(I)化合物在制备治疗与MLL相关的疾病的药物中的用途。在制备过程中，通过取代、成环、以及去保护等一系列反应，得到本发明化合物。

USPTO Abstract

本申请涉及式(I)所示的一类具有生物抑制活性的取代的杂环化合物及其制备方法和用途。所述用途包括式(I)化合物在制备治疗与MLL相关的疾病的药物中的用途。在制备过程中，通过取代、成环、以及去保护等一系列反应，得到本发明化合物。

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: CN121358726A
Jurisdiction: CN
Classification: —
Expires: 2026-01-16
Drug substance claim: No
Drug product claim: No
Assignee: Capital Pharmaceutical Holdings Beijing Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.